Provided by Tiger Trade Technology Pte. Ltd.

Agree

65.88
+0.85001.31%
Post-market: 66.240.3600+0.55%19:30 EDT
Volume:1.59M
Turnover:104.42M
Market Cap:8.19B
PE:35.58
High:66.16
Open:65.21
Low:64.98
Close:65.03
52wk High:82.08
52wk Low:64.98
Shares:124.38M
Float Shares:122.18M
Volume Ratio:0.90
T/O Rate:1.30%
Dividend:3.14
Dividend Rate:4.77%
EPS(TTM):1.85
EPS(LYR):1.77
ROE:3.70%
ROA:2.40%
PB:1.29
PE(LYR):37.22

Loading ...

Lepu Biopharma Delivers Revenue Growth as ADC Pipeline Advances

TIPRANKS
·
Aug 19

Agree Realty Declares Monthly Distribution of R$ 0.12 Per Unit, Payable Aug. 20

Reuters
·
Aug 18

Akari Therapeutics Reaffirmed Buy as Analyst Keeps $27 Price Target on Advancing Trop2 ADC and Strengthened PH1 Platform

TIPRANKS
·
Aug 17

Breakthrough: AstraZeneca and Daiichi Sankyo's ADC Shows Strong Efficacy in First-Line Lung Cancer Therapy

Stock News
·
Aug 17

ADC Therapeutics price target lowered to $5 from $10 at Guggenheim

TIPRANKS
·
Aug 17

ADC Therapeutics reports Q2 adjusted EPS (11c) vs. (25c) last year

TIPRANKS
·
Aug 17

Agree Realty (ADC) Earnings Call Highlights Growth, Discipline

TIPRANKS
·
Aug 15

ADC Therapeutics Balances LOTIS-5 Regulatory Risk With LOTIS-7 Opportunity, RBC Says

MT Newswires Live
·
Aug 14

Boan Biotechnology Advances First-in-Class CD228 ADC With Positive Early Trial Data

TIPRANKS
·
Aug 14

Bioan Biotech's BA1302 (CD228 ADC) Completes China Phase Ia Clinical Study

Stock News
·
Aug 14

Innate Pharma launches €22.5m share placement to fund ADC pipeline and extend runway

TIPRANKS
·
Aug 14

Press Release: Akari Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Progress of AKTX-101 Towards Phase 1 and Strategic Collaboration for Its ADC Payload Platform

Dow Jones
·
Aug 14

Press Release: Kyntra Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

Dow Jones
·
Aug 14

Agree Realty Declares Monthly Distribution of R$ 0.12 Per Unit, Payable Sept. 21

Reuters
·
Aug 14

ADC Therapeutics Reports Q2 2026 Results, Reassesses ZYNLONTA Path

TIPRANKS
·
Aug 13

ADC Therapeutics Q2 2026 Earnings: Lower Spending Narrows the Loss

TradingKey
·
Aug 13

ADC Therapeutics Q2 Adj. EPS $(0.11) Beats $(0.21) Estimate, Sales $19.248M Miss $19.376M Estimate

Benzinga Earnings
·
Aug 13

Press Release: ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates

Dow Jones
·
Aug 13

Press Release: Pyxis Oncology Reports Second Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones

Dow Jones
·
Aug 13

Agree Realty (ADC) Lifts Dividend As Income Narrative Keeps Valuation In Focus

Simply Wall St.
·
Aug 13